Abstract 36P
Background
Soft tissue sarcomas (STS) are a group of rare and heterogeneous tumors with different clinical and biological behaviors. Better prognosis has been associated to an inflamed tumor microenvironment (TME) characterized by the presence of tertiary lymphoid structures (TLSs) rich in B cells. However, studies are still needed to better characterize cellular and molecular components of the TME the that could favor or hamper B cell organization in STS-associated TLSs.
Methods
The transcriptomic immune profiling of STS TME was performed using the Human Immunology V2 Panel and the NanoString nCounter platform on 33 STS biopsies or surgical samples. Patients with primary or locally recurrent STS were enrolled and treated at the Careggi Hospital (Florence, Italy; RESEARCH study). Results were validated by retrieving RNA-sequencing and clinical data for 164 STS patients from The Cancer Genome Atlas (TCGA) SARC project.
Results
We investigated the impact of gene signatures discriminating for specific immune cells and we found a significant association with relapse-free survival (RFS) only for germinal center (GC) B cell- and T helper 17 (Th17) cell-related signatures (p < 0.05). We observed a correlation between GC-B and Th17 signatures (r = 0.77, p < 0.0001), and the combination of both GC B and Th17 signatures was associated with better RFS, while low expression of both GC B and Th17 signatures was associated with the worst survival outcome (p = 0.035). The prognostic value of the GC-B/Th17 signature was confirmed on data from TCGA SARC project for both RFS (p = 0.016) and overall survival (p = 0.014). Differential gene expression analysis showed a more inflamed landscape in GC-B/Th17-high tumors. Conversely, the upregulation of genes encoding immunosuppressive molecules and genes related to tumor-associated macrophages with an immunosuppressive phenotype, were observed in GC-B/Th17-low tumors.
Conclusions
Our data identified a novel prognostic signature composed of GC B cell- and Th17 cell-related genes for STS patients, and suggest a potential collaboration between GC B cells and Th17 cells in mediating antitumor immune responses and potentially TLS formation in STS.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
90P - HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): a phase II trial
Presenter: HAIBIN ZHANG
Session: Poster Display
91P - A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma
Presenter: Wei zhang
Session: Poster Display
92P - TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A propensity score matching study
Presenter: hongjie Cai
Session: Poster Display
93P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: a real-world, retrospective, multicentric study.
Presenter: Margherita Rimini
Session: Poster Display
94P - First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma
Presenter: Qin-qin Liu
Session: Poster Display
95P - A single-arm, multicenter phase ? trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Junsheng Wang
Session: Poster Display
97P - ICI for patients with MSS metastatic colorectal cancer
Presenter: Zayana Sangadzhieva
Session: Poster Display
Resources:
Abstract
99P - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
Presenter: Hongnan Mo
Session: Poster Display
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display